Alignment Healthcare LLC

Alignment Healthcare has filed a motion to dismiss a whistleblower lawsuit in which a former company executive accused the Medicare-driven health insurer of manipulating its finances to boost its stock price. Shares of the Orange, California-based firm plunged in early July after media reports indicated that ex-employee Hakan Kardes filed the case in a federal court in Santa Ana. Citing a court filing, Bloomberg reported that the company has dismissed the allegations as a case of sour grapes. Alignment said in a statement that a third-party investigation found Kardes' Sarbanes-Oxley whistleblower claims are false and there is no basis for his allegations. The company cited multiple reasons for the dismissal, including that the plaintiff filed whistleblower claims too late, and added that Kardes sued only after realizing that an in-house restructuring initiative didn't roll out as he expected.

Alignment Healthcare raised its full-year 2026 guidance following a second quarter that saw membership jump 31.5% to about 294,100 and adjusted EBITDA climb 60% year over year to $106 million for the first half. The company now expects 2026 revenues of $5.195 billion to $5.225 billion, membership of 298,000 to 301,000, adjusted gross profit of $630 million to $650 million, and adjusted EBITDA of $145 million to $163 million. However, management plans heavier clinical, artificial intelligence, and expansion spending in the second half, with third-quarter adjusted EBITDA projected at just $20 million to $30 million compared with $68.1 million in the second quarter. The company’s adjusted medical benefit ratio improved 40 basis points year over year to 86.3%, its lowest since going public, while adjusted selling, general and administrative expenses fell to 8.7% of revenues. The stock carries a Zacks Rank #3 (Hold).

Alignment Healthcare reported second-quarter 2026 membership growth of 31.5% to about 294,100 and revenue growth of 31.6% to $1.34 billion, while raising its full-year outlook to 298,000–301,000 members and revenues of $5.20–$5.23 billion. Adjusted gross profit rose 35.3% to $182.9 million, the adjusted medical benefit ratio improved 40 basis points to 86.3%, and adjusted EBITDA climbed 48.4% to $68.1 million. Despite the operating momentum, the stock trades at a forward price-to-earnings ratio of 68.4 and an enterprise value-to-EBITDA ratio of 53.0, and management guided for third-quarter adjusted EBITDA of only $20–$30 million due to higher-acuity new members and seasonal spending. With a $14 price target only modestly above the recent $13.68 close, Zacks Investment Research rates the stock a Hold, citing limited near-term upside and second-half execution risk.

Alignment Healthcare shares rose 10.7% after the company reported quarterly revenues of US$1.24 billion, a 33.3% year-on-year increase, with earnings per share exceeding expectations and membership expanding by 48,500 to 284,800. Analysts sharply raised full-year earnings estimates, and the company secured higher Star Ratings across all member plans for the 2026 payment year, which directly influence reimbursement and could support revenue per member. Despite softer near-term EBITDA guidance, the combination of robust revenue growth, membership gains, and improved quality ratings strengthens the near-term earnings catalyst, though core policy and competition risks remain.

Alignment Healthcare shares appear undervalued, with a Discounted Cash Flow model estimating intrinsic value at about $43.72 per share compared to the current price of $24.01, implying a roughly 45.1% discount. The stock has returned about 321.2% over three years, yet the DCF analysis, based on trailing free cash flow of approximately $204.1 million, suggests the market is pricing the senior-focused health insurer below its projected cash generation. Additionally, Alignment Healthcare trades on a price-to-sales ratio of about 1.2 times, below the healthcare industry average of around 1.5 times and a peer group average of about 2.3 times, while screening as undervalued in five of six valuation tests. The key question remains whether the company can scale its membership and control medical costs without reimbursement or execution setbacks that could challenge the apparent discount.

StockStory identified Five Below, Alignment Healthcare, and CNX Resources as three growth stocks with strong competitive advantages and explosive upside potential. Five Below, the discount retailer, posted 25.9% annual revenue growth and averaged 8% same-store sales growth over two years, with expected revenue growth of 10% in the next 12 months. Alignment Healthcare, a Medicare Advantage provider, achieved 41.8% annual revenue growth and 45.4% over two years, while its earnings per share grew 28.5% annually over four years and free cash flow margin expanded by 11 percentage points over five years. CNX Resources, a natural gas producer, reported 15% revenue growth, a 68% gross margin, and a 23.4% free cash flow margin, with EBITDA profits rising over five years due to improved efficiency.

StockStory highlights Alignment Healthcare as a Wall Street favorite with strong fundamentals, while warning investors to avoid Akamai Technologies and Sinclair despite consensus price targets implying returns above 20%. Alignment Healthcare, a Medicare Advantage provider, posted 45.4% annual revenue growth over two years and a free cash flow margin that jumped 11 percentage points over five years. Akamai faces underwhelming billings growth of 6.8%, a gross margin of 58.3% that trails competitors, and an expected 25.3 percentage point drop in free cash flow margin. Sinclair has seen sales decline 11.4% annually over five years and carries a 7× net-debt-to-EBITDA ratio that may force dilutive equity offerings.

Zacks Investment Research has identified four top-ranked stocks with sound liquidity and strong growth potential that investors may consider to maximize returns. The four stocks are Alignment Healthcare, Argan, Agilysys, and Ciena Corporation. The screening used current, quick, and cash ratios between 1 and 3, asset utilization above the industry average, a Zacks Rank of 1, and a Growth Score of B or better, narrowing a universe of over 7,700 stocks to just 15. Alignment Healthcare reported first-quarter 2026 revenues of $1.24 billion, up 33.3% year over year, with health plan membership rising 30.9% to 284,800. Argan posted first-quarter fiscal 2027 revenues of $291 million, a 50% increase, and ended the quarter with a backlog of $2.8 billion. Agilysys delivered fiscal 2026 revenues of $319.3 million, up 15.9%, and guided fiscal 2027 revenues to $365–$370 million with subscription revenue growth north of 30%. Ciena's fiscal second-quarter 2026 revenues surged 39.5% to $1.57 billion, driven by cloud demand, and it expects third-quarter revenues of $1.625 billion.

CVS Health posted the strongest first-quarter results among 12 tracked health insurance providers, with revenues of $100.4 billion beating analyst expectations by 6.3%. The group overall exceeded revenue consensus by 1.4%, while next-quarter guidance was in line. Centene also outperformed, reporting $49.94 billion in revenue and topping estimates by 6.2%, while Cencora lagged with $78.36 billion, missing forecasts by 3.9%. Progyny and Alignment Healthcare rounded out the cohort, with Progyny raising full-year guidance the most among peers and Alignment adding 48,500 customers to reach 284,800 total members.

Alignment Healthcare has demonstrated strong business momentum with revenue growing at a 33.6% compounded annual rate over the past five years, outpacing the average healthcare company. The company's full-year earnings per share turned positive over the last four years, signaling a key inflection point. Free cash flow margin expanded by 11 percentage points over five years, reaching 5.3% on a trailing 12-month basis, reflecting improved capital efficiency. Despite these fundamentals, the stock has underperformed, trading at $19.95 per share with a 2.9% decline over the past six months, compared to the S&P 500's 12.4% gain.